Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term dosing safety and efficacy of romiplostim in pediatric patients with immune thrombocytopenia purpura (ITP) completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Thrombocytopenia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP | Phase 3 | Status: COMPLETED | Results posted: 2019-01-29